Literature DB >> 35198853

Innocent until proven guilty? Longstanding atrial ectopy preceding cardiac rhabdomyoma diagnosis in tuberous sclerosis complex: a case report.

Alison J Howell1, Rachel D Vanderlaan2, Christopher Z Lam3, Katie L Losenno1, Juan Putra4, Olivier Villemain1.   

Abstract

BACKGROUND: Cardiac rhabdomyoma are the most common cardiac tumour in childhood and are associated with tuberous sclerosis complex (TSC) up to 96% of infant cases. They classically manifest in the foetal and neonatal period, undergo spontaneous regression in the first years of life and are associated with arrhythmia in part due to interruption of normal conduction pathways by the tumour. CASE
SUMMARY: We present a case of a 3-year-old boy with a long-standing history of atrial ectopy who was incidentally found to be in atrial flutter due to a new, rapidly growing cardiac rhabdomyoma impacting ventricular function. The boy was later confirmed with further investigation and TSC1 gene test to have TSC. DISCUSSION: Cardiac Rhabdomyoma does not always present in the infantile period. Any ongoing or new cardiac concern in patient with TSC, even if seemingly minor, should warrant more frequent cardiac evaluation and investigation.
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

Entities:  

Keywords:  Atrial flutter; Cardiac rhabdomyoma; Case report; Paediatric cardiology; Tuberous sclerosis complex

Year:  2022        PMID: 35198853      PMCID: PMC8855693          DOI: 10.1093/ehjcr/ytac068

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


De novo cardiac rhabdomyoma growth occurs outside of the foetal and neonatal period and can be the presenting feature of tuberous sclerosis complex. More frequent surveillance for rhabdomyoma should take place if there are ongoing or new cardiac concerns.

Introduction

Cardiac rhabdomyoma are the most common cardiac tumour in childhood and are associated with tuberous sclerosis complex (TSC) up to 96% of infant cases. These benign hamartomas classically manifest in the foetal and neonatal period and undergo spontaneous regression in the first years of life often with resolution. They are associated with arrhythmia in part due to interruption of normal conduction pathways by the tumour, creating abnormal atria-ventricular connections and ectopic electrical foci. We present a case of a 3-year-old boy with longstanding atrial ectopy who presented with a new, right atrial tumour causing sustained atrial arrhythmia and impacting ventricular function. Following surgical resection, the diagnosis of cardiac rhabdomyoma was made and the patient later found to have the TSC1 gene mutation.

Case presentation

A healthy 3-year-old male presented for routine paediatric cardiology follow-up. He was initially referred due to the presence of atrial ectopy during a hospital admission for left orchidopexy at 6 months of age. Otherwise, his history was unremarkable with an uneventful antenatal course and normal 20-week anomaly scan. There was no family history of cardiac disease or TSC and no other parental concerns during follow-up except for mild speech delay. At 9 and 18 months, 12-lead electrocardiogram (ECG) were normal and 24-h Holter monitoring noted sinus rhythm with a combined ectopy burden of 11%. Isolated atrial ectopy accounted for 7% of beats and ventricular ectopy 4%. There were no runs of ventricular tachyarrhythmia and the longest run of premature atrial contractions was 3 beats at 158 b.p.m. Echocardiograms performed at the same time as these Holter recordings were normal. Although clinically very well, at this appointment he was in atrial flutter on his 12-lead ECG. His examination was unremarkable with normal heart sounds and no murmurs heard. Dermal, respiratory, urinary, and visual system were normal as well. Echocardiogram revealed a severely dilated right atrium with a new large mass (6.4 × 3.1 cm) in the right atrium attached to the interatrial septum (see ). The mass was prolapsing through the tricuspid valve into the right ventricle during diastole causing no significant obstruction to inflow but with moderate tricuspid regurgitation through multiple jets. The right ventricular function was reduced (ejection fraction = 39%) but left ventricular function preserved (ejection fraction = 61%). The conventional blood work (including liver enzymes and cardiac biomarkers) was unremarkable. A sedate cardiac magnetic resonance imaging (MRI) demonstrated a heterogeneous, multilobulated right atrial mass but was not able to refine the differential to a single diagnosis. There were few cystic and myxomatous components, no brisk intense early enhancement and no evidence of infiltrative disease (see ).
Figure 1

Normal echocardiogram at 18 months old and abnormal echo at 3 years old. Apical four-chamber view demonstrating a new large solitary mass (6.4 × 3.1 cm) originating in the right atrium and protruding through the tricuspid valve.

Figure 2

Cardiac magnetic resonance imaging. Pre-operative cardiac magnetic resonance imaging demonstrating a large lobulated right atrial mass that shows heterogeneous mildly hyperintense signal on T2-weighted sequences (A), no early enhancement on first pass perfusion (B), along with mild heterogeneous enhancement on both post-contrast SSFP cines (C) and 3D delayed gadolinium enhancement sequences (D).

Normal echocardiogram at 18 months old and abnormal echo at 3 years old. Apical four-chamber view demonstrating a new large solitary mass (6.4 × 3.1 cm) originating in the right atrium and protruding through the tricuspid valve. Cardiac magnetic resonance imaging. Pre-operative cardiac magnetic resonance imaging demonstrating a large lobulated right atrial mass that shows heterogeneous mildly hyperintense signal on T2-weighted sequences (A), no early enhancement on first pass perfusion (B), along with mild heterogeneous enhancement on both post-contrast SSFP cines (C) and 3D delayed gadolinium enhancement sequences (D). Given the potential obstruction to inflow, reduced ventricular function and persistent arrhythmia he underwent surgical excision. At the time of surgery, the mass was found to originate from the superior vena cava and right atrial junction (see ) which were consequently reconstructed in addition to a tricuspid valve annuloplasty.
Figure 3

Rhabdomyoma explorations. (A) Operative findings: one lobulated soft tissue mass, pale tan in colour measuring 6.5 cm × 5.5 cm × 2.4 cm (arrows). (B) Histology: the classic combination of large rounded polygonal cells with strands of cytoplasm extending between nuclei and cell membrane (spider cells)—(haematoxylin and eosin, 10×). (C) Axial T2 FLAIR magnetic resonance imaging images of the brain show multiple subcortical tubers (arrows) and calcified subependymal nodules (dashed arrows).

Rhabdomyoma explorations. (A) Operative findings: one lobulated soft tissue mass, pale tan in colour measuring 6.5 cm × 5.5 cm × 2.4 cm (arrows). (B) Histology: the classic combination of large rounded polygonal cells with strands of cytoplasm extending between nuclei and cell membrane (spider cells)—(haematoxylin and eosin, 10×). (C) Axial T2 FLAIR magnetic resonance imaging images of the brain show multiple subcortical tubers (arrows) and calcified subependymal nodules (dashed arrows). His post-operative course was uncomplicated. The echocardiogram on post-operative Day 3 showed a good result with a good biventricular systolic function and no residual mass. From a rhythm perspective, the flutter immediately resolved following excision of the mass and he remained in sinus rhythm with no significant ectopy noted on subsequent 24-h Holter monitoring at discharge. Histology of the tumour revealed large rounded polygonal cells with pathognomonic spider cells confirming the tumour to be a cardiac rhabdomyoma (see ). He underwent a brain MRI which revealed multiple cortical and subcortical tubers together with calcified subependymal nodules (see ). Abdominal ultrasound demonstrated bilateral renal angiolipomas. Subsequent genetic testing confirmed a likely pathogenic variant TSC1 gene (TSC1.c.1641_1642delAC (p.Pro548Lysfs*15)) according to the ACMG 2015 variant classification guidelines. Cardiac follow-up at 1 year confirmed good ventricular function on echocardiogram with no recurrence or new tumour growth. Three 24-h Holter monitors throughout the year demonstrated no arrhythmia. He was referred to the TSC clinic at our institution for ongoing follow-up. Routine EEG showed epileptiform discharges from the centro-parietal head regions but he has not had any clinical seizures and did not require seizure medication.

Discussion

We present a case of TSC with cardiac rhabdomyoma growing in size in the first years of life. From the singular history of this patient who had a regular cardiological follow-up for clinically insignificant ectopy, we have confirmation that this cardiac rhabdomyoma appeared de novo after 18 months of life and grew significantly during the 3rd year of life of this patient. The current International Tuberous Sclerosis Consensus Group guidelines concerning echocardiographic surveillance for cardiac rhabdomyoma recommend foetal scanning if there is high suspicion of TSC with imaging later in gestation as tumours can enlarge in the 3rd trimester. At least one postnatal echocardiogram is proposed due to reported haemodynamic compromise after birth. In the absence of inflow/outflow obstruction and ventricular dysfunction, follow-up echocardiography is not recommended in the first year of life but may be considered between 1 and 3 years to document regression. Currently, no further follow-up is recommended once this has occurred unless prompted by new cardiac concerns. The association between cardiac rhabdomyoma and TSC is due to the mutations in the TSC1 or TSC2 genes, leading to disruption of mTOR signalling pathway with resultant tumourigenesis secondary to loss of inhibition of cell growth and proliferation. Recently, exogenous mTOR inhibitors have been used to reduce the size of cardiac rhabdomyomas in haemodynamically significant lesions and there is suggestion that long-term therapy with these medications may alleviate the clinical manifestations of TSC. The predominance of growth of cardiac rhabdomyoma in the foetal period is believed to be due to propagation by trans-placental oestrogen, with regression occurring after this influence dissipates. But it is a misconception that growth is limited to the infantile years. A large multi-national natural history study of TSC found the mean age of cardiac rhabdomyoma diagnosis to be 3.1 years and a previously published literature review observed 20% of diagnoses are made over the age of 6 years, though it is unclear whether these tumours had stabilized since the infant period or presented as denovo childhood growth. Although they are the only cardiac tumour known to spontaneously regress, it is incorrect to think regression is the definitive rule. In congruence with other studies, a prospective cohort of 154 TSC patients with cardiac rhabdomyoma noted complete regression in only 18% and partial regression in 50% of patients. Additionally, denovo growth outside of the neonatal period does occur with a recent case highlighting a new, rapidly growing cardiac rhabdomyoma in a 2-year-old patient following previous surgical resection and documented regression of multiple ventricular rhabdomyomas. Interestingly this new, solitary tumour was located in the right atrium, an uncommon site of origin but the same as our case report. The theoretical hormonal influence on growth is further supported by the appearance of denovo tumours, albeit small and without hemodynamic consequence, in 4% of TSC patients around the time of puberty. Jozwiak et al.’s cohort demonstrated new tumour growth in six patients aged 10–15 years, three of which had no prior history of cardiac rhabdomyoma and five of which were female. However, this pathophysiological theory is not applicable in our case due to the patient’s atypical age. Another unusual characteristic of this tumour is the demonstration of rapid growth more in keeping with a true neoplasm rather than hamartoma. Such expansile growth is seen in adult cellular cardiac rhabdomyomas which demonstrate cellular proliferation not seen in childhood hamartoma. However, these tumours differ histologically with smaller cell size and fewer vacuolated spider cells which are abundant in childhood cardiac rhabdomyoma. Histology in our case was highly typical of cardiac rhabdomyoma seen in childhood.

Summary

Clinicians must counsel appropriately on the basis of the natural course of any disease. Cardiac rhabdomyomas associated with TSC do not always occur in the foetal and neonatal period, do not universally regress or maintain a stable size, and there is potential for new tumour growth outside of the first years of life. This case highlights the importance of surveillance echocardiography in not only all new TSC diagnoses but throughout childhood and adolescence for all confirmed TSC with even seemingly minor cardiac concerns.

Lead author biography

Alison J. Howell trained in Pediatrics at Great Ormond Street Hospital and is completing her Paediatric Cardiology training at The Hospital for Sick Children, Canada. Her intended subspeciality is Echocardiography with an interest in heart function in repaired congenital heart disease.

Supplementary material

Supplementary material is available at European Heart Journal - Case Reports online. Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data. Consent: The authors confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patient in line with COPE guidance. Conflict of interest: None declared. Funding: None declared. Click here for additional data file.
TimeEvents
Foetal periodMultiples normal scans
9 months oldSuspicion of cardiac arrhythmia—normal echocardiography
18 months oldRegular follow-up—normal echocardiography
3 years oldDiagnostic of atrial flutter
Finding of new massive intracardiac tumour
Day +2 post-tumour diagnosticCardiac surgery—extensive excision
Histology confirm the rhabdomyoma
Weeks following the surgical excisionConfirmation of the tuberous sclerosis complex diagnosis: brain tubers, renal angiolipomas, TSC1 mutations
4 years old (+1 year post-surgical excision)Asymptomatic. Normal echocardiography
  12 in total

1.  Natural history of cardiac rhabdomyoma in infancy and childhood.

Authors:  J F Smythe; J D Dyck; J F Smallhorn; R M Freedom
Journal:  Am J Cardiol       Date:  1990-11-15       Impact factor: 2.778

2.  Clinical and genotype studies of cardiac tumors in 154 patients with tuberous sclerosis complex.

Authors:  Sergiusz Jóźwiak; Katarzyna Kotulska; Jolanta Kasprzyk-Obara; Dorota Domańska-Pakieła; Małgorzata Tomyn-Drabik; Penelope Roberts; David Kwiatkowski
Journal:  Pediatrics       Date:  2006-08-28       Impact factor: 7.124

3.  Multiple Accessory Pathways in an Infant With Cardiac Rhabdomyomas and Tuberous Sclerosis.

Authors:  Christopher M Janson; Veneel Bhupathiraju; Saurabh Talathi; Kristi Glotzbach
Journal:  JACC Clin Electrophysiol       Date:  2018-04

4.  Adult cellular rhabdomyoma of the heart: a report of 3 cases.

Authors:  Allen P Burke; Cara Gatto-Weis; Janet E Griego; Kenneth S Ellington; Renu Virmani
Journal:  Hum Pathol       Date:  2002-11       Impact factor: 3.466

5.  New-onset cardiac rhabdomyoma beyond infancy in a patient with tuberous sclerosis complex.

Authors:  Nikhil M Thatte; Kristine J Guleserian; Surendranath R Veeram Reddy
Journal:  Cardiol Young       Date:  2015-07-14       Impact factor: 1.093

6.  Possible prevention of tuberous sclerosis complex lesions.

Authors:  Katarzyna Kotulska; Julita Borkowska; Sergiusz Jozwiak
Journal:  Pediatrics       Date:  2013-06-03       Impact factor: 7.124

7.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

Review 8.  Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group.

Authors:  Robert B Hinton; Ashwin Prakash; Robb L Romp; Darcy A Krueger; Timothy K Knilans
Journal:  J Am Heart Assoc       Date:  2014-11-25       Impact factor: 5.501

9.  TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients.

Authors:  John C Kingswood; Guillaume B d'Augères; Elena Belousova; José C Ferreira; Tom Carter; Ramon Castellana; Vincent Cottin; Paolo Curatolo; Maria Dahlin; Petrus J de Vries; Martha Feucht; Carla Fladrowski; Gabriella Gislimberti; Christoph Hertzberg; Sergiusz Jozwiak; John A Lawson; Alfons Macaya; Rima Nabbout; Finbar O'Callaghan; Mirjana P Benedik; Jiong Qin; Ruben Marques; Valentin Sander; Matthias Sauter; Yukitoshi Takahashi; Renaud Touraine; Sotiris Youroukos; Bernard Zonnenberg; Anna C Jansen
Journal:  Orphanet J Rare Dis       Date:  2017-01-05       Impact factor: 4.123

10.  Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.

Authors:  Afshin Saffari; Ines Brösse; Adelheid Wiemer-Kruel; Bernd Wilken; Paula Kreuzaler; Andreas Hahn; Matthias K Bernhard; Cornelis M van Tilburg; Georg F Hoffmann; Matthias Gorenflo; Sven Hethey; Olaf Kaiser; Stefan Kölker; Robert Wagner; Olaf Witt; Andreas Merkenschlager; Andreas Möckel; Timo Roser; Jan-Ulrich Schlump; Antje Serfling; Juliane Spiegler; Till Milde; Andreas Ziegler; Steffen Syrbe
Journal:  Orphanet J Rare Dis       Date:  2019-05-03       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.